Endomyocardial Fibrosis


Article Author:
Karan Bhatti


Article Editor:
Juan Lopez-Mattei


Editors In Chief:
Michael Firstenberg
Lawrence Greiten


Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes


Updated:
6/4/2019 7:16:59 PM

Introduction

Endomyocardial fibrosis (EMF) is a rare disease in North America but common in the tropical and subtropical regions of the developing world. It is characterized by fibrosis of the left ventricular and right ventricular endocardium which cause restrictive cardiomyopathy. In endemic areas of Africa, endomyocardial fibrosis is an important cause of heart failure accounting for up to 20% of the cases. Currently, the exact etiology and pathogenesis of the disease remain unknown. However, its pathology resembles conditions such as eosinophilic cardiomyopathy and hypereosinophilic syndrome. As a result, EMF is sometimes considered part of a single disease process that also includes Loffler endocarditis (eosinophilic endomyocardial fibrosis).[1][2][3]

Etiology

The exact cause of the fibrotic process of EMF remains currently unknown. Nonetheless, multiple factors have been proposed.[4][5][5][6]

Eosinophilia

It has been recognized that EMF is similar to the fibrotic stage of Loffler endocarditis, as severe chronic eosinophilia has been known to cause endomyocardial damage and fibrosis. Even though there is a resemblance between the two conditions, eosinophilia is not always seen in patients with EMF.

Infectious

Due to the geographical location of the disease, several infectious pathogens have been considered; these include Plasmodium species, Microfilaria, Schistosoma, Helminths, arboviruses, and Toxoplasma. Nonetheless, there has been no correlation with a single organism in EMF.

Environmental Exposure

Cerium is a chemical element and has been found in increased quantities in affected areas. As a result, it has been hypothesized to be a risk factor for developing EMF. Cerium can contaminate soil and as well as food items.

Immunologic

Anti-myosin antibodies have been detected in some patients with EMF. Nonetheless, anti-myosin antibodies are also present in several conditions such as rheumatic heart disease, Dressler syndrome, and post-cardiac transplant rejection. So the presence of this marker is non-specific.

Genetic

A familial component has been proposed but it is currently unclear whether this is a result of a genetic or environmental cause or a combination of both.

Epidemiology

Endomyocardial fibrosis is most prevalent in the tropical regions of Africa, Asia, and South America. It is a disease that mainly affects young adults of lower socioeconomic status. A study in Uganda indicated a bimodal peak at 10 and 30 years of age. Studies on gender distribution have been mixed, and currently, there is no specific data on gender predisposition.

Pathophysiology

EMF involves both the right and left ventricle in 50% of cases. Forty percent of cases have solely the left ventricle involved, and in the remaining 10% of cases, the right ventricle is involved. The hallmark characteristic of the condition is the fibrotic obliteration of the affected ventricle. The underlying process produces focal or diffuse endocardial thickening and fibrosis which leads to restrictive physiology. Endomyocardial fibrosis involves the apices of the right and left ventricle. In the left ventricle, the fibrosis typically extends from the apex to the posterior leaflet of the mitral valve, sparing the anterior mitral valve leaflet and the left ventricular outflow tract. Furthermore, the fibrosis in some cases can involve the papillary muscles and chordae tendineae resulting in atrioventricular valve regurgitation and distortion. In advanced stages, endocardial calcific deposits and thrombus formation can occur. This process does not involve the epicardium, and coronary artery obstruction is very uncommon. There is no involvement of the extracardiac organs.[7][8]

Histopathology

Histology typically demonstrates fibrotic thickening of the endocardium due to acellular collage tissue deposition with the proliferation of fibrous tissue in the underlying myocardium.

History and Physical

The clinical presentation of EMF depends on the cardiac chamber involved and its severity. The initial phase of the illness is the acute carditis phase, characterized by a febrile illness and in severe cases cardiogenic shock. Those who survive the acute illness progress into sub-acute and chronic phase. Majority of patients present during the chronic burnt out phase. Therefore, at presentation most patients present with advanced complications such as heart failure, arrhythmias and/or thromboembolic disease.

Patients with predominantly right ventricular involvement present with ascites, hepatomegaly, lower extremity edema, elevated jugular venous pressure and tricuspid regurgitation. Giant V waves and a rapid Y decent can be seen in right ventricular involvement. In patients with left ventricular involvement, dyspnea is the predominant symptom. Fatigue, cachexia, and orthopnea are also commonly present. Mitral regurgitation can occur due to the fibrotic involvement of the chordae tendineae and posterior mitral valve leaflet. In addition, findings of pulmonary hypertension and S3, S4 gallop are also frequently present.

Evaluation

Electrocardiogram

In advanced stages of EMF, low-voltage QRS complexes and nonspecific ST and T wave abnormalities are observed. Also, atrioventricular blocks, intraventricular conduction delay, and right or left bundle branch blocks are frequently seen. Left atrial enlargement and atrial arrhythmias occur in advanced cases of left sides EMF.  

Echocardiography

Echocardiography is the diagnostic modality of choice when making the diagnosis of a classical presentation of EMF. Via this modality, the pathological hallmarks of the disease such as apical obliteration and endocardial surface thrombi may be seen. Microbubble contrast aids in enhancing the left ventricular cavity and allowing better imaging quality for diagnosis. Furthermore, atrioventricular valve abnormalities and restrictive filling pattern can be identified. In right-sided EMF, obliteration of the trabecular aspect of the right ventricular cavity is noted. With further disease advancement, there is a reduction of the right ventricular cavity volume and worsening tricuspid regurgitation due to tricuspid annular dilatation. Spontaneous echo contrast and right atrial thrombi are also commonly seen. In left-sided EMF, the ventricular apex is also obliterated causing restricted movement of the apex due to fibrosis.  The basal portion of the ventricle becomes hypercontractile as a compensatory mechanism. Fibrotic involvement of the posterior mitral valve leaflet can cause severe eccentric mitral regurgitation. In both left and right sided EMF, the atria are enlarged.

Transmitral inflow using Doppler echocardiography, the duration of deceleration time and isovolumetric relaxation time are all consistent with a restrictive filling pattern. In early diastole, there is brisk filling with very poor filling observed in the rest of diastole. Also, in a large number of patients decreased flow propagation velocity (vp) has been demonstrated.

Cardiac Hemodynamics

On cardiac catheterization, the left ventricular tracing typically shows a dip and plateau pattern which is consistent with restrictive ventricular filling. Elevated Left ventricular end diastolic pressure is also commonly observed. Left ventricular angiography reveals characteristic obliteration of the apex of the involved ventricle.

Electron Beam Computed Tomography Scanning

Obliteration of the apex and inflow tract if present can be demonstrated. In addition, the fibrosis can be visualized by a band of low attenuation within the endocardium.

Cardiovascular Magnetic Resonance Imaging

Imaging with late gadolinium enhancement can highlight myocardial fibrosis. Contrast-enhanced MRI has become a more frequent diagnostic modality in the non-invasive diagnosis of endomyocardial fibrosis.

Chest X-ray

Various degrees of cardiomegaly from mild to severe, atrial enlargement and pulmonary vascular congestion can be identified. Occasionally endomyocardial calcification can be seen.

Laboratory

In some cases, eosinophilia can be seen. Hypoalbuminemia is also commonly present due to protein-losing enteropathy.

Treatment / Management

Medical care currently remains very challenging as one-third to one-half of patients with advanced disease die within 2 years. Atrial fibrillation is a poor prognostic factor; however rate control strategies can offer patients symptomatic relief. A limited role exists for immunosuppressive therapies as the majority of the patients present long after any possible period of myocarditis. Symptomatic therapy can be provided with diuretic therapy. These patients could benefit to some degree from ACE inhibitors and beta-blockers. Anticoagulation is recommended in patients who have a thrombus identified by imaging. Surgery in the correct setting can increase survival and especially in patients with advanced heart failure. The most commonly used approach is endocardectomy combined with valvular replacement when indicated. It is to be noted that the mortality rate for surgery can approach 15% to 20%.[9][10]

Prognosis

The prognosis for EMF is poor as the incidence of sudden cardiac death due to arrhythmia, thromboembolic disease, and end-stage heart failure is very high. As a result, the mean survival rate is approximately 2 years.

Enhancing Healthcare Team Outcomes

EMF is best managed with a multidisciplinary team including cardiology nurses. Unfortunately, the prognosis for most patients is poor. Medical therapy is considered palliative but may prolong life for a few years. Surgery is done to remove the excess fibrotic tissue and replace the damaged valves, but it carries a very high mortality.


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Endomyocardial Fibrosis - Questions

Take a quiz of the questions on this article.

Take Quiz
A 33-year-old female who recently immigrated from Mozambique complains of fatigue, increased dyspnea with exertion and weight gain. She also reports that recently she has had to sleep upright due to difficulty breathing while sleeping at night. The patient reports she had a febrile illness many years ago which spontaneously resolved. She did not seek medical care at the time. On examination, her temperature is 37.2 Celsius, heart rate of 94 beats per minute, respiratory rate 16/minute, and blood pressure 102/64 mmHg. Examination reveals elevated jugular venous pressure, regular rhythm with an S3, palpable liver, abdominal swelling with ascites and 3+ lower extremity edema. What test is most likely to reveal the diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 42-year-old male from Uganda has been recently diagnosed with endomyocardial fibrosis. He asks what is the prognosis of this condition. What is the approximate mean survival rate?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 30-year-old female with heart failure secondary to known endomyocardial fibrosis undergoes a coronary angiogram for hemodynamic assessment. What would be expected to be seen on the left ventricular tracing?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 50-year-old male with a recent diagnosis of endomyocardial fibrosis presents with worsening dyspnea for the past one week and a 12-pound weight gain. On examination, the patient is in mild distress. Temperature is 37.0 C, a pulse of 108 beats per minute, respiratory rate is 20/minute, and blood pressure 118/64 mmHg. Examination reveals an elevated jugular venous pressure, tachycardia with regular rhythm with an S3, positive hepatojugular reflex, and 2+ lower extremity edema. Laboratory data is unremarkable except for a sodium level of 128 meq/L. What is the next step in management?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Endomyocardial Fibrosis - References

References

Kumar P,Chandrashekhara SH,Kumar S,Malhi AS, Loeffler's endocarditis with isolated left ventricular involvement on cardiac MRI. BMJ case reports. 2019 Apr 20;     [PubMed]
Chetboul V,Passavin P,Trehiou-Sechi E,Gouni V,Poissonnier C,Pouchelon JL,Desquilbet L, Clinical, epidemiological and echocardiographic features and prognostic factors in cats with restrictive cardiomyopathy: A retrospective study of 92 cases (2001-2015). Journal of veterinary internal medicine. 2019 Mar 28;     [PubMed]
Inderbitzin DT,Krapf C,Buser M,Mestres CA, Surgical resection of restrictive left ventricular endomyocardial fibrosis. European heart journal. 2019 Mar 11;     [PubMed]
Crişan S,Tint D,Petrescu L, Therapeutic Advances in Emergency Cardiology: A Focus on Acute Myocarditis. American journal of therapeutics. 2019 Mar/Apr;     [PubMed]
Urmeneta Ulloa J,Fraile Sanz C,Cabrera JA, Endomyocardial fibrosis. Davies disease. Multimodality imaging. Revista clinica espanola. 2019 Feb 20;     [PubMed]
Asai T,Miyashita F,Nota H,Vigers PN, Tricuspid valve relocation with endomyocardial fibrosis removal for Löeffler's endocarditis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2019 Feb 8;     [PubMed]
Kraef C,Ramharter M, [Cardiac manifestations of tropical diseases]. Herz. 2019 Feb;     [PubMed]
Sharma A,Pandey NN,Malhi AS,Kumar S, Complex right atrial mass in endomyocardial fibrosis: a diagnostic dilemma. BMJ case reports. 2019 Jan 4;     [PubMed]
Lanier GM,Fallon JT,Naidu SS, Role of Advanced Testing: Invasive Hemodynamics, Endomyocardial Biopsy, and Cardiopulmonary Exercise Testing. Cardiology clinics. 2019 Feb;     [PubMed]
Ogbogu PU,Rosing DR,Horne MK 3rd, Cardiovascular manifestations of hypereosinophilic syndromes. Immunology and allergy clinics of North America. 2007 Aug;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Surgery-Cardiac. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Surgery-Cardiac, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Surgery-Cardiac, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Surgery-Cardiac. When it is time for the Surgery-Cardiac board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Surgery-Cardiac.